Inhibiting the entire receptor complex prevents IL-6 signal transduction to inflammatory ... Conclusion: Tocilizumab, a novel IL-6R inhibitor, may be beneficial for the treatment of RA in patients ...

Bristol–Myers Squibb (BMS) has entered a potential ∼US$1 billion agreement with Alder Biopharmaceuticals involving Alder's lead drug ALD518, a humanized monoclonal antibody specific for ...

"Similar trends" that fell short of statistical significance were also seen when JAK inhibitors were compared with less ...

AVTOZMA® is Celltrion’s twelfth biosimilar to obtain marketing authorization in the European Union. Stay tuned to Big Molecule Watch for more regulatory updates on biosimilars.

Two Phase II studies and one Phase III study have been conducted with tocilizumab to date. The primary endpoint for many trials of drugs to treat RA is a 20% improvement in the majority of a set ...